viewMedlab Clinical Ltd

Medlab Clinical achieves over $3 million revenue for June quarter, shares rise

Medlab is a medical research company with a track record of bringing its nutraceutical and cannabis products to market.

growth concept
Medlab shares are trading up 11.4% to 39 cents today

Medlab Clinical Ltd (ASX:MDC) achieved total revenue in excess of $3 million for the June quarter representing a 135% increase on last year's June quarter.

On the research front, Medlab is focused on chronic disease markets including pain management and depression where global markets represent significant earnings opportunities.

Medlab’s patented nutraceutical product in the market, NRGBiotic™, is being evaluated as a treatment for the gut and depression – progress is steady with encouraging early data.

Research work is also progressing using its patented cannabis-based medicines NanaBis™ and NanaBidial™, which also continues to yield strong, encouraging results.

Converting research and product development into commercial success

In both nutraceutical and medical cannabis categories, significant progress has been made commercialising products through increased sales.

Medlab has its own growing distribution team together with third party distributors where appropriate to maximise the potential global market penetration.

Product range can be found in over 3,000 Australian pharmacies

Medlab’s CEO Dr Sean Hall said: “it’s apparent that a number of our clients remember me from when I coowned and managed BioCeuticals.

“Although BioCeuticals was sold several years ago, this time has given me the ability to leverage solid research into the Medlab nutraceutical range and I believe this is what sets us apart from other ranges.”

READ: Medlab Clinical signs distribution deal for NanaBis

In late May 2019, Medlabs executed a heads of agreement with Thai-listed Mega Lifesciences (BKK:MEGA) for the further global distribution of NanaBis™. 

The terms of the Heads of Agreement provide for both parties to negotiate various commercial terms involving potential global territories for NanaBis™. 

NanaBis is a highly purified proprietary blend of cannabis molecules cannabidiol (CBD) and tetrahydrocannabinol (THC).

It is delivered into the body using Medlab’s patented sub-micron delivery platform NanoCelle™.

NanaBis is a buccal (side of cheek) spray currently in the second stage of an Australian advanced cancer pain trial.

Patients can access it under the government’s Special Access Scheme and it is currently before several regulatory agencies for potential fast track drug approval pathways.

READ: Medlab Clinical receives human ethics approval for cannabis-based pain management medicine trial

Medlab has two cannabis-based medicines, NanaBis™ and NanaBidial™, which contain formulations of tetrahydrocannabinol (THC) and cannabidiol (CBD).

NanaBis™ has a 1:1 ratio of CBD:THC and NanaBidial™ has a 18:2 ratio of CBD:THC.

NanaBis™ is currently in clinical trial at Royal North Shore Hospital.

Notably, both medicines are available to Australian patients for compassionate use under the government Special Access Scheme (SAS).

Quick facts: Medlab Clinical Ltd

Price: 0.18 AUD

Market: ASX
Market Cap: $50.34 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medlab Clinical Ltd named herein, including the promotion by the Company of Medlab Clinical Ltd in any Content on the Site, the Company...


Medlab Clinical's Dr Sean Hall details new FeverMates agreement

Medlab Clinical Ltd's (ASX:MDC) Dr Sean Hall caught up with Proactive's Andrew Scott after signing a Heads of Agreement (HoA) with Randall Communications Pty Ltd - trading as FeverMates. The deal will help to expand Medlab’s nutraceutical business in new foreign and domestic...

on 6/4/20

3 min read